UY25888A1 - Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias - Google Patents
Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratoriasInfo
- Publication number
- UY25888A1 UY25888A1 UY25888A UY25888A UY25888A1 UY 25888 A1 UY25888 A1 UY 25888A1 UY 25888 A UY25888 A UY 25888A UY 25888 A UY25888 A UY 25888A UY 25888 A1 UY25888 A1 UY 25888A1
- Authority
- UY
- Uruguay
- Prior art keywords
- derivatives
- mmp
- treatment
- inhibitors
- matrix
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 4
- 239000011159 matrix material Substances 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- -1 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 abstract 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 abstract 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 abstract 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 abstract 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 abstract 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 abstract 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 abstract 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 102100030416 Stromelysin-1 Human genes 0.000 abstract 1
- 101710108790 Stromelysin-1 Proteins 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de los ácidos 4-biarilbutírico y 5-biarilpentanoico con actividad inhibitoria de la metalproterasa de la matriz de fórmula general: (T)x-A-B-D-E-CO2H-, donde: (T)x-A representa un resto aromático o heteroaromático sustituido o no sustituido seleccionado de un grupo de los representados en la figura 1, donde R1 es H o alquilo C1-C3 y cada T representa un grupo sustituyente y x es 0, 1 o 2; B representa un enlace o un anillo aromático o heteroaromático opcionalmente sustituido seleccionado de uno de los grupos representados en la figura 2 D es uno de los grupos representados en la figura 3; E es una cadena de 2 o 3 átomos de carbono que lleva de 1 a 3 sustituyentes R6. Ejemplos de derivados seleccionados: Ácido (+)-2-[2-(1,3-dioxo-1,3-dihidro-2H-isoindol-2-il)etil]-4-(4'etoxi-[1,1'-bifenil]-4-il)-4-oxobutanoico; Ácido (+)-4-(4'-cloro[1,1'-bifenil]-4-il)-2-[2-(1,3-dioxo-1,3-dihidro-2H-isoindol-2-il)etil]-4-oxobutanoico; entre otros. Se incluye el uso de los derivados de los ácidos 4-biarilbutírico y 5-biarilpentanoico sustituidos, donde al menos una de lasunidades A, B, T y R6 comprende un anillo heteroaromático como inhibidores de la metaloproteasa de la matriz para la prevención y tratamiento de enfermedades respiratorias, y a composiciones farmacéuticas que los contienen y así como un procedimiento para su uso. En especial estos compuestos pueden ser utilizados para tratar o prevenir trastornos mediados por la MMP-2, MMP-3, MMP9, MMP-12 y/o MMP-1, como entre otras posibilidades para el tratamiento del asma, neuropatía obstructiva crónica, fibrosis quística.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9828845.9A GB9828845D0 (en) | 1998-12-30 | 1998-12-30 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases |
| GBGB9922709.2A GB9922709D0 (en) | 1999-09-24 | 1999-09-24 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25888A1 true UY25888A1 (es) | 2001-08-27 |
Family
ID=26314942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25888A UY25888A1 (es) | 1998-12-30 | 1999-12-30 | Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6900194B1 (es) |
| EP (1) | EP1140768A1 (es) |
| JP (1) | JP2002534404A (es) |
| KR (1) | KR20010101325A (es) |
| CN (1) | CN1337932A (es) |
| AR (1) | AR035472A1 (es) |
| AU (1) | AU1982500A (es) |
| BR (1) | BR9916669A (es) |
| CA (1) | CA2356053A1 (es) |
| CO (1) | CO5261506A1 (es) |
| HK (1) | HK1043981A1 (es) |
| IL (1) | IL143594A0 (es) |
| PE (1) | PE20001339A1 (es) |
| TR (1) | TR200101970T2 (es) |
| UY (1) | UY25888A1 (es) |
| WO (1) | WO2000040539A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1031349A1 (en) * | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| ES2386263T3 (es) * | 2000-03-21 | 2012-08-14 | Emisphere Technologies, Inc. | Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato |
| US7262325B2 (en) | 2000-06-02 | 2007-08-28 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| US20030045449A1 (en) * | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| EP1394159A1 (fr) * | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| KR101274309B1 (ko) * | 2005-02-22 | 2013-06-13 | 랜박시 래보러터리스 리미티드 | 천식 및 기타 질병의 치료를 위한 기질 메탈로프로테나제저해제로서 5-페닐-펜탄산 유도체 |
| SG160363A1 (en) * | 2006-04-17 | 2010-04-29 | Sumitomo Chemical Company Limt | Ester of cyclic carboxylic acid |
| JP5338035B2 (ja) * | 2006-04-17 | 2013-11-13 | 住友化学株式会社 | 多環式ラクタム類の製造方法 |
| CA2812319A1 (en) * | 2010-09-24 | 2012-03-29 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
| CN103086947A (zh) * | 2011-11-04 | 2013-05-08 | 赵庆春 | 具有抗血管生成活性的邻苯二甲酰亚胺类化合物及其用途 |
| JP5861884B2 (ja) * | 2012-03-29 | 2016-02-16 | 荒川化学工業株式会社 | エキソ型ノルボルネン化合物の製造方法 |
| EP3126358A1 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen |
| WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
| WO2015150366A1 (de) * | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Cyclisch substituierte phenolether-derivate und ihre verwendung |
| CA2944617A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
| US20170121315A1 (en) * | 2014-06-12 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1106195A (en) * | 1994-11-09 | 1996-06-06 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
| US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| HRP950558A2 (en) | 1994-11-15 | 1997-12-31 | Scott M. Wilhelm | Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors |
| US5886022A (en) | 1995-06-05 | 1999-03-23 | Bayer Corporation | Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors |
| CO5070565A1 (es) | 1996-05-15 | 2001-08-28 | Bayer Corp | Inhibicion de las metaloproteasas de matriz por compuestos de fenetilo sustituido y sus composiciones farmaceuticas |
| WO1998009940A1 (en) | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| MY117687A (en) * | 1996-10-31 | 2004-07-31 | Bayer Corp | Substituted 4-biphenyl-4-hydroxybutric acid derivatives as matrix metalloprotease inhibitors |
| WO1999018079A1 (en) | 1997-10-06 | 1999-04-15 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
-
1999
- 1999-12-20 WO PCT/EP1999/010110 patent/WO2000040539A1/en not_active Ceased
- 1999-12-20 CA CA002356053A patent/CA2356053A1/en not_active Abandoned
- 1999-12-20 JP JP2000592250A patent/JP2002534404A/ja active Pending
- 1999-12-20 TR TR2001/01970T patent/TR200101970T2/xx unknown
- 1999-12-20 IL IL14359499A patent/IL143594A0/xx unknown
- 1999-12-20 BR BR9916669-0A patent/BR9916669A/pt not_active Application Discontinuation
- 1999-12-20 US US09/869,668 patent/US6900194B1/en not_active Expired - Fee Related
- 1999-12-20 AU AU19825/00A patent/AU1982500A/en not_active Abandoned
- 1999-12-20 KR KR1020017008314A patent/KR20010101325A/ko not_active Withdrawn
- 1999-12-20 EP EP99963582A patent/EP1140768A1/en not_active Withdrawn
- 1999-12-20 HK HK02105193.2A patent/HK1043981A1/zh unknown
- 1999-12-20 CN CN99816404A patent/CN1337932A/zh active Pending
- 1999-12-28 PE PE1999001333A patent/PE20001339A1/es not_active Application Discontinuation
- 1999-12-28 AR ARP990106795A patent/AR035472A1/es not_active Application Discontinuation
- 1999-12-30 UY UY25888A patent/UY25888A1/es unknown
- 1999-12-30 CO CO99081622A patent/CO5261506A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002534404A (ja) | 2002-10-15 |
| PE20001339A1 (es) | 2001-01-11 |
| EP1140768A1 (en) | 2001-10-10 |
| IL143594A0 (en) | 2002-04-21 |
| CA2356053A1 (en) | 2000-07-13 |
| CN1337932A (zh) | 2002-02-27 |
| HK1043981A1 (zh) | 2002-10-04 |
| AR035472A1 (es) | 2004-06-02 |
| KR20010101325A (ko) | 2001-11-14 |
| TR200101970T2 (tr) | 2002-03-21 |
| CO5261506A1 (es) | 2003-03-31 |
| WO2000040539A1 (en) | 2000-07-13 |
| US6900194B1 (en) | 2005-05-31 |
| BR9916669A (pt) | 2001-10-16 |
| AU1982500A (en) | 2000-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25888A1 (es) | Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias | |
| ATE411288T1 (de) | Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) | |
| BR0109353A (pt) | Cadeia lateral heterocìclica contendo inibidores de metaloprotease | |
| DK0778834T3 (da) | Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2 | |
| ECSP055847A (es) | Derivados de dihidropiranoindol-3,4-diona sustituidos y derivados de 2-hidroximetilindol del ácido 3-oxoacético sustituidos como inhibidores del inhibidor del activador de plasminógeno 1 (pai-1) | |
| PE20011314A1 (es) | DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA | |
| BR9712085A (pt) | Inibidores de metaloprotease heterocìclicos | |
| DE60132309D1 (de) | Amin-derivate zur behandlung von apoptosis | |
| UY27357A1 (es) | Nuevos agentes antidiabéticos . | |
| BR0009167A (pt) | Inibidores de enzima impdh | |
| BR0011130A (pt) | Inibidores de metaloproteases | |
| ES2161291T3 (es) | N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa. | |
| BG106013A (en) | New compounds and compositions as protease inhibitors | |
| EA200300306A1 (ru) | Спиропиримидин-2,4,6-трионовые ингибиторы металлопротеиназы | |
| FI962749A0 (fi) | Uusia heterosyklisiä yhdisteitä | |
| ATE284860T1 (de) | Neue verwendung von phenylheteroalkylamin- derivaten | |
| DE69825603D1 (de) | 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2 | |
| AR009358A1 (es) | Compuesto espirociclico inhibidor de la metaloproteasa | |
| ECSP045469A (es) | El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas | |
| PE20040698A1 (es) | Derivados de isoindolina | |
| CO4820432A1 (es) | Composiciones farmaceuticas para el tratamiento de rinitis que comprenden acido 2-(4-(difenilmetil)-1-piperacinil)-ace- tico o amida derivada y un compuesto seleccionado de pseudoe fedrina,fenilpropanolamina y fenilefrina | |
| BR0109328A (pt) | Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica | |
| MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
| ATE253359T1 (de) | Antithrombotische mittel | |
| AR044014A1 (es) | Composiciones farmaceuticas para administracion intranasal de acido [2-(8,9-dioxo-2, 6-diazabiciclo [5.2.0) non-1 (7) -en-2-il)alquil]-fosfonico y derivados y metodos de utilizacion de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20090416 |